Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic Database

Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic Database

Epidermal growth factor receptor 2 (<i>ERBB2/HER2</i>) is a critical biomarker in gastric cancer management, but the clinical implications of specific ERBB2 mutations remain poorly characterized. Methods/Results: We investigated the <i>ERBB2</i> R678Q mutation, utilizing the...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuhei Suzuki, Manabu Seino, Hidenori Sato, Yosuke Saito, Koki Saito, Yuta Yamada, Koshi Takahashi, Ryosuke Kumanishi, Tadahisa Fukui
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Current Issues in Molecular Biology
Subjects:
gastric cancer
ERBB2
HER2
R678Q mutation
genomic testing
oxaliplatin
Online Access:https://www.mdpi.com/1467-3045/47/6/430
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/1467-3045/47/6/430

Similar Items